NASDAQ$RYTM
Rhythm Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Rhythm Pharmaceuticals reported Q1 2025 revenue of $32.7M with a net loss of $49.5M and diluted EPS of $(0.81).
Total revenue rose to $32.7 million on Imcivree uptake and rare-disease commercial execution. Net loss was $49.5 million, or $0.81 per share, as R&D and SG&A remained elevated while the company scales its precision-medicine portfolio.
- Q1 revenue $32.7M (+26% YoY).
- Net loss $49.5M; diluted EPS $(0.81).
- Imcivree and pipeline expansion drive top-line growth.
- Convertible preferred financing supports balance sheet.
Headline financials
Revenue & EPS history
Rhythm Pharmaceuticals · Revenue · Quarterly
$32.7M
Forward guidance
Rhythm focuses on Imcivree label expansion and pipeline milestones; traditional quarterly EPS guidance not provided.
Tailwinds
- Imcivree commercial uptake in rare obesity syndromes.
- Pipeline programs in hypothalamic obesity.
- Strong cash position from recent financing.
Headwinds
- Net losses until revenue scale broadens.
- R&D spend on late-stage trials.
- Payer coverage and access timelines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+3.1%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+5.4%
Avg return
30 days after
53%
18 / 34 earnings
Positive
+40.8%
Q2 2022
Best reaction
-15.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.2% | +10.3% | +2.5% | |
| Q4 2025 | -0.9% | -9.7% | -23.5% | |
| Q3 2025 | -7.7% | -11.8% | -7.1% | |
| Q1 2025 | +2.9% | -6.0% | +8.6% | |
| Q4 2024 | +4.5% | +2.7% | +7.4% | |
| Q3 2024 | +18.2% | +27.1% | +9.1% | |
| Q2 2024 | -1.1% | +2.8% | +9.6% | |
| Q1 2024 | -11.3% | -10.8% | -9.6% | |
| Q4 2023 | -7.5% | -5.7% | -16.9% | |
| Q3 2023 | +1.2% | +5.1% | +40.3% | |
| Q2 2023 | +36.3% | +37.0% | +45.8% | |
| Q1 2023 | -8.4% | -17.4% | -15.0% | |
| Q4 2022 | +0.1% | -9.8% | -26.6% | |
| Q3 2022 | -2.5% | +15.5% | +15.7% | |
| Q2 2022 | +40.8% | +62.6% | +103.5% | |
| Q1 2022 | -12.5% | -32.1% | -46.0% | |
| Q4 2021 | +21.3% | +21.7% | +51.2% | |
| Q3 2021 | +14.4% | +14.9% | -24.0% | |
| Q2 2021 | -15.7% | -17.5% | -22.1% | |
| Q1 2021 | -0.1% | +2.6% | -10.5% | |
| Q4 2020 | +3.2% | +0.2% | -17.9% | |
| Q3 2020 | +8.8% | +7.9% | +51.2% | |
| Q2 2020 | -2.4% | -1.8% | +55.2% | |
| Q1 2020 | +7.1% | +8.7% | +10.9% | |
| Q4 2019 | +3.0% | -5.4% | -22.1% | |
| Q3 2019 | +0.6% | -1.3% | +5.3% | |
| Q2 2019 | -4.7% | -2.9% | +11.7% | |
| Q1 2019 | -0.7% | -1.0% | -2.4% | |
| Q4 2018 | +5.8% | +8.2% | +1.6% | |
| Q3 2018 | -12.3% | -15.3% | -13.1% | |
| Q2 2018 | -1.3% | -2.8% | -5.9% | |
| Q1 2018 | +17.8% | +21.2% | +29.9% | |
| Q4 2017 | +6.9% | -16.3% | -24.0% | |
| Q3 2017 | -5.7% | +1.3% | +10.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro